Obesity and its associated metabolic syndromes represent a growing global challenge, yet mechanistic understanding of this pathology and current therapeutics are unsatisfactory. We discovered that CD4 + T lymphocytes, resident in visceral adipose tissue (VAT), control insulin resistance in mice with diet-induced obesity (DIO). Analyses of human tissue suggest that a similar process may also occur in humans. DIO VAT-associated T cells show severely biased T cell receptor V a repertoires, suggesting antigenspecific expansion. CD4 + T lymphocyte control of glucose homeostasis is compromised in DIO progression, when VAT accumulates pathogenic interferon-c (IFN-c)-secreting T helper type 1 (T H 1) cells, overwhelming static numbers of T H 2 (CD4 + GATA-binding protein-3 (GATA-3) + ) and regulatory forkhead box P3 (Foxp3) + T cells. CD4 + (but not CD8 + ) T cell transfer into lymphocyte-free Rag1-null DIO mice reversed weight gain and insulin resistance, predominantly through T H 2 cells. In obese WT and ob/ob (leptindeficient) mice, brief treatment with CD3-specific antibody or its F(ab¢) 2 fragment, reduces the predominance of T H 1 cells over Foxp3 + cells, reversing insulin resistance for months, despite continuation of a high-fat diet. Our data suggest that the progression of obesity-associated metabolic abnormalities is under the pathophysiological control of CD4 + T cells. The eventual failure of this control, with expanding adiposity and pathogenic VAT T cells, can successfully be reversed by immunotherapy.
Obesity and its associated metabolic syndromes represent a growing global challenge, yet mechanistic understanding of this pathology and current therapeutics are unsatisfactory. We discovered that CD4 + T lymphocytes, resident in visceral adipose tissue (VAT), control insulin resistance in mice with diet-induced obesity (DIO). Analyses of human tissue suggest that a similar process may also occur in humans. DIO VAT-associated T cells show severely biased T cell receptor V a repertoires, suggesting antigenspecific expansion. CD4 + T lymphocyte control of glucose homeostasis is compromised in DIO progression, when VAT accumulates pathogenic interferon-c (IFN-c)-secreting T helper type 1 (T H 1) cells, overwhelming static numbers of T H 2 (CD4 + GATA-binding protein-3 (GATA-3) + ) and regulatory forkhead box P3 (Foxp3) + T cells. CD4 + (but not CD8 + ) T cell transfer into lymphocyte-free Rag1-null DIO mice reversed weight gain and insulin resistance, predominantly through T H 2 cells. In obese WT and ob/ob (leptindeficient) mice, brief treatment with CD3-specific antibody or its F(ab¢) 2 fragment, reduces the predominance of T H 1 cells over Foxp3 + cells, reversing insulin resistance for months, despite continuation of a high-fat diet. Our data suggest that the progression of obesity-associated metabolic abnormalities is under the pathophysiological control of CD4 + T cells. The eventual failure of this control, with expanding adiposity and pathogenic VAT T cells, can successfully be reversed by immunotherapy.
The incidence of obesity is increasing worldwide, which is quite problematic as it is a high-risk factor for development of the metabolic syndrome-a melange of pathological conditions that include insulin resistance, glucose intolerance and toxicity, hepatic steatosis and dyslipidemia, as well as the risk of developing type 2 diabetes 1 . Type 2 diabetes and obesity both involve genetic and environmental factors 2 , which represent a major global cause of morbidity and mortality, as current nonsurgical therapies are inadequate 3 .
Together, the above elements contribute to persistent beta cell stress, dysfunction and type 2 diabetes risk. However, progression of metabolic syndrome to overt diabetes is not easily predicted; many patients with metabolic syndrome never convert, whereas some progress only transiently. Likewise, while some obese individuals progress to metabolic syndrome, others only have mild metabolic abnormalities 2, 4 . In any case, adipose tissue inflammation is viewed as a promoter of progression, but the underlying mechanisms remain unclear, as does the nature of what limits or halts progression in individuals with persisting metabolic syndrome, as well as what drives type 2 diabetes progression in those who do convert.
Obesity-associated insulin resistance is a core element of type 2 diabetes development. The impairment of insulin sensitivity involves multiple organs, prominently including hypertrophic adipose tissue with an associated rise in serum and tissue levels of fatty acids, adipokines, and proinflammatory molecules such as interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) 1, 5 . TNF-a can be produced by both adipocytes and, in particular, macrophages 6, 7 . Macrophages accumulate in both VAT and subcutaneous adipose tissue (SAT). The roles of fat-resident macrophages in obesity-induced insulinresistance differ, with VAT being the principal driver of metabolic syndrome progression [8] [9] [10] .
Macrophage activation is modified by T cells. IFN-g-secreting T cells (T H 1), as well as those secreting IL-17 (T H 17), enhance macrophage proinflammatory functions by inducing the release of IL-1, IL-6 and TNF-a. In contrast, anti-inflammatory IL-4 and IL-13secreting T cells (T H 2), as well as CD4 + Foxp3 + regulatory T cells, modify macrophage function by inducing their differentiation into anti-inflammatory, IL-10-secreting M2, or 'alternatively activated' , macrophages (AAMs) 11, 12 . AAMs are characterized by abundant surface expression of macrophage mannose receptor (MMR) and intracellular arginase activity 13 . Increased tissue levels of IL-10 improve insulin sensitivity in liver and fat 14, 15 , and AAMs in adipose tissue have been shown to normalize some of the metabolic abnormalities associated with diet-induced obesity in animal models 11, 15 . Strategies increasing the number of AAMs or cells that induce them (for example, T H 2 or CD4 + Foxp3 + T cells) might be of therapeutic promise in insulin resistance and type 2 diabetes.
CD4 + and CD8 + T cells enter VAT and SAT of obese mice and humans 16, 17 . The function of these fat-associated T cells and their conceivable roles in obesity, glucose homeostasis or both are unknown, nor are their antigen specificities, activation history or T sublineage profiles known 18 .
We investigated the impact of T cells on the glucose homeostasis of C57BL/6 (B6) mice with DIO. We discovered a progressive bias in the recruitment to and expansion of proinflammatory T H 1, but not T H 17 T cells in adipose tissue, with a body mass-dependent, progressive decline in the proportions of anti-inflammatory CD4 + Foxp3 + regulatory T cells observed in obese mice and humans. We used independent experimental model systems in mice to delineate several fatresident immune elements with distinct impacts on weight gain, insulin resistance and glucose homeostasis. Among these, our observation of VAT-specific T cell receptor bias was most unexpected, as it is typically associated with antigen-specific and/or pathogen-specific T cell expansion as well as autoimmunity [19] [20] [21] [22] .
The predominant T cell effect on glucose homeostasis, revealed by CD4 + T cell reconstitution studies in lymphocyte-free DIO Rag1-null mice, was improvement of glucose tolerance, enhanced insulin-sensitivity and lessening of weight gain. We identified the subsets involved and probed the overall T cell impact in fully developed DIO, using immunotherapy with a clinically effective CD3-specific antibody or its nonmitogenic F(ab¢) 2 fragment 23 . Both therapies substantially normalized insulin resistance and glucose homeostasis, selectively restoring CD4 + Foxp3 + T cell pools in VAT. Treatment was effective for months after a short course of injections, despite unchanged high-fat diet consumption. These results suggest a dual role of fat-associated T lineage cells, which initially mitigate inflammation-induced insulin resistance until VAT-driven T H 1 expansion overwhelms this protective effect, a process that can be targeted and corrected therapeutically.
RESULTS

Characterization of fat-associated T cells
We characterized the numbers and subsets of fat-associated T cells from inguinal SAT and epididymal VAT of 14-to 18-week-old high-fat diet (HFD)-fed and normal chow diet (NCD)-fed B6 mice, consistently collecting about 4 Â 10 5 CD3 + T cells per g VAT and SAT. The fat-associated T cell subset distribution varied somewhat, with a trend toward higher CD8 to CD4 ratios, in particular in VAT of HFD-fed mice compared to VAT of regular diet controls ( Fig. 1a ). VAT from lean and obese mice also contained pools of CD3 + CD4 À CD8 À lymphocytes (that is, natural killer (NK), NKT and Tg/d lineage cells) 24 , and these were largely unaffected by obesity ( Fig. 1a ).
CD4 + effector T cells can generally be subdivided into proinflammatory cells (T H 1, T H 17) and anti-inflammatory and regulatory sublineages (T H 2, Foxp3 + ). There were fewer IFN-g-secreting T H 1 cells in SAT than in VAT from NCD and HFD B6 mice ( Fig. 1b ). HFD generated a progressive IFN-g bias among fat-associated T cells, whereas it diminished the small VAT T H 17 sublineage ( Fig. 1b) . Compared to VAT of NCD-fed mice, the proportion of regulatory CD4 + Foxp3 + T cells in VAT from HFD-fed mice was 70% lower, probably contributing to the proinflammatory VAT profiles of obese mice (Fig. 1c ). The ratio of T H 1 to Foxp3 + T cells in VAT increased from B1.5:1 in NCD-fed mice to B6.5:1 in DIO mice. In terms of absolute numbers, approximately three times more T H 1 cells accumulated per gram of fat in HFD-fed mice ( Fig. 1d ), whereas numbers of CD4 + Foxp3 + T cells per g of VAT varied little (Fig. 1d ). The numbers of T H 1 cells in adipose tissue thus represent the dynamic variable affected by diet-induced obesity. The high proportion of CD4 + Foxp3 + T cells in VAT of lean mice, which are progressively diluted by IFN-g-producing cells in progressive DIO, suggests one candidate cellular mechanism by which progressive obesity leads to worsening metabolic control.
Observations in lean and obese humans were strikingly analogous. In VAT from obese humans ( Fig. 1e) , T H 1 cells that express the lineage-specific Tbet transcription factor 25 outnumbered Foxp3 + T cells with a ratio of B12:1, whereas the ratio was B6:1 in VAT of lean humans (Fig. 1e) . The relative proportion of T H 1 to Foxp3 + cells in VAT correlated with body mass index (BMI) ( Fig. 1e , r 2 ¼ 0.62). As in mice, we observed human fat-associated T cells clustered around blood vessels, some scattered between adipocytes ( Supplementary  Fig. 1a ). We commonly observed Foxp3 + fatassociated T cells in close proximity to monocytes and macrophages ( Supplementary Fig. 1b ), predicting possible interactions with fat-associated monocytes and macrophages.
Tissue-selective lymphocyte accumulation can reflect a number of mechanisms, including cognate events, involving T cell receptor engagements with its major histocompatibility complex-antigen conjugates. Although we did not expect to find selective T cell receptor (TCR) engagement of VAT-associated T cells, we decided to formally rule this possibility out by using ovalbumin (OVA)-specific, OT2 TCR transgenic mice 26 . These B6 mice developed metabolic complications of DIO ( Supplementary Fig. 2a -c). A small proportion of transgenic OT2 T cells can bypass TCRa allelic exclusion and undergo random, secondary V a rearrangements, yielding a second surface TCR that can recognize non-OVA antigens 27 . Such cells can be identified through their reduced surface expression of the original, transgenic TCR V a relative to CD3.
There were small pools (4-7%) of T cells with secondary TCRa rearrangements in spleens, VAT and SAT of young OT2 mice ( Fig. 1f ). Beginning at around 6 weeks of age, secondary TCRa rearrangements slowly and selectively increased thereafter (7-21%) in VAT of all mice, but, in particular, in HFD-fed OT2 mice ( Fig. 1f ). This VAT tissuespecific effect indicates a strong selective pressure toward a non-OVA antigen(s); that is, an adipose tissue antigen or antigen modification present only in VAT but not in SAT or elsewhere. Thus, unexpectedly, T cell expansion in VAT seems, at least in part, antigen driven.
We sought further support for this notion and PCR amplified each of the 20 TCR V a -encoding genes in highly purified T cells with secondary TCR V a rearrangements. These cells had been sorted by FACS from spleens and VAT of obese, 16-week-old OT2 mice; wildtype (WT) B6 spleens served as controls that expressed the expected full spectrum of TCRa families (Fig. 1g ). TCR V a usage in spleen and VAT T cells from obese OT2 mice differed substantially; only some of the receptors were systemically shared, including the transgenic V a2 (Fig. 1g ). VAT T cells had lost V a3 but gained strong expression of V a5 and V a18 (Fig. 1g) . Spectra-typing of the CDR3 region in OT2 TCRaencoding genes emphasized the strong selection pressures in VAT for very narrow TCRa diversity and negative pressure against selection of the majority of systemic TCR V a s, thus generating an impressive TCR V a bias among VAT T cells, which includes unique V a5 (417 base pairs) and V a18 (393 base pairs) regions ( Supplementary Fig. 3) .
Motivated by the VAT tissue-specific TCR selection bias and to rule out possible effects of the TCR transgene, we repeated this analysis but included sorted CD4 + TCRb + NK1.1 À VAT T cells from HFD-fed as well as NCD-fed B6 WT mice ( Fig. 1g) . We observed a strong TCR V a bias in VAT of lean (10 of 20 TCR V a families expressed) and, more so, in VAT of HFD-fed mice (only seven of the same ten V a families used in lean mice) ( Fig. 1g) . Spectra-typing of the CDR3 region showed markedly altered diversity in VAT TCR V a repertoires of DIO versus lean B6 mice ( Supplementary Fig. 4 ). These results suggest antigenspecific expansion of T cell repertoires in VAT of lean mice, with increasing bias in progressive obesity, probably driven by adipose tissue changes that occur as a result of obesity. Tissue-driven TCR bias is common in organ-selective autoimmune disorders [19] [20] [21] [22] . However, this process has not previously been associated with obesity or type 2 diabetes, and will require identification of the relevant tissue self epitopes to formally prove autoreactivity.
Metabolic role of T cells in obesity
HFD-fed Rag1-null mice lack lymphocytes, gain more weight and show greater visceral adiposity than HFD-fed WT mice ( Fig. 2a,b ). Increased visceral obesity in HFD-fed Rag1-null mice was mostly due to notable adipocyte hypertrophy ( Fig. 2c and Supplementary Fig. 5 ). There were no significant abnormalities in body weight, adipose tissue mass or adipocyte size in Rag1-null mice on NCD ( Fig. 2a-c) , nor were there differences in food intake, CO 2 output or O 2 consumption between HFD-fed Rag1-null and HFD-fed WT mice (Fig. 2d) . insulin tolerance test (i) after transfer of CD4 + OT2 TCRa hi (CD4 + OT2 hi ) T cells or CD4 + T cells into HFD-fed Rag1-null mice (n ¼ 5 per group, *P o 0.0001, two-way ANOVA). (j) Fasting glucose (left) and fasting insulin (middle) in CD4 + or CD4 + OT2 TCRa hi (OT2 hi )-transferred HFD-fed Rag1-null mice (n ¼ 5 mice per group, *P o 0.05, t test). Right, weight gain after transfer of CD4 + or CD4 + OT2 hi TCRa hi T cells into HFD-fed Rag1-null mice (n ¼ 5 mice per group, *P o 0.004, t test). All FACS plots include cell percentages of the corresponding quadrants; histograms represent means ± s.d.
Glucose and insulin tolerances in 14-week-old, HFD-fed Rag1-null mice were severely impaired, with fasting glucose at diabetic levels ( Fig. 2e,f) , fasting hyperinsulinemia ( Fig. 2f) and low insulin sensitivity upon insulin challenge (Fig. 2g) . Rag1-null mice on NCD showed nonsignificant trends toward poorer glucose tolerance and increased insulin resistance. However, a significant elevation of fasting blood glucose ( Fig. 2e-g) implies that the metabolic role of lymphocytes may be physiological and occurs even in the absence of a hypercaloric diet.
CD4 + T cells regulate obesity and glucose homeostasis
The DIO Rag1-null phenotype delineated an overall protective role of lymphocytes in weight gain and insulin resistance. To identify lymphocyte subsets involved in this process, we reconstituted 12-week-old HFD-fed Rag1-null mice with 5 Â 10 6 CD4 + or CD8 + T cells, each specifically depleted of CD49b + NK and NKT cells, CD11b + monocytes and macrophages and CD19 + and CD45R + B cells before transfer.
Two weeks after transfer, the cells had populated spleen, SAT and VAT with high purity (B95%, Fig. 3a ). CD4 + (but not CD8 + ) T cell reconstitution lowered weight gain quite notably by 2-4 weeks after transfer (Fig. 3b) , despite similar food intake, CO 2 output and O 2 consumption in all mice ( Supplementary Fig. 6a,b ). Lesser weight gain was apparent in SAT and, even more so, in VAT (Fig. 3b) , and it was associated with smaller adipocyte size in both fat compartments ( Fig. 3c and Supplementary Fig. 5 ), when CD4 + T cell-transferred HFD-fed Rag1-null recipients were compared to CD8 + T cell-transferred HFD-fed Rag1-null recipients or Rag1-null control mice. CD4 + T cell transfer also lowered serum levels of obesity-associated adipokines such as leptin, resistin and monocyte chemoattractant protein-1 (MCP-1) ( Supplementary Fig. 6c ), and it normalized glucose tolerance, with lower fasting insulin and glucose levels and improved insulin sensitivity within 2 weeks ( Fig. 3d-f) .
To determine the role of cognate, TCR-dependent events, we purified OVA-specific T cells from OT2 TCR-transgenic B6 mice by sorting cells without secondary rearrangements. Two weeks after adoptive transfer of these CD4 + OT2 TCR V a hi lymphocytes into HFD-fed Rag1-null mice, there were still almost no T cells with secondary rearrangements in spleens or fat (Fig. 3g) . Notably, the presence of exclusively OVA-specific T cells in VAT failed to improve glucose tolerance (Fig. 3h) , insulin sensitivity (Fig. 3i) , fasting blood glucose (Fig. 3j) , fasting insulin (Fig. 3j) or body weight (Fig. 3j) .
These results indicate that CD4 + T cells in VAT mediate the positive global controls of DIO-associated metabolic abnormalities in an antigen-specific fashion.
CD4 + Foxp3 + T cells are regulators of inflammation, and CD4 + T cell transfer into HFD-fed Rag1-null mice slowly repopulated Rag1-null VAT with CD4 + Foxp3 + T cells, by 2-3% 2 weeks after transfer (Fig. 4a) . To determine whether CD4 + Foxp3 + T cells are essential in the regulation of glucose homeostasis after cell transfer, we sorted and transferred CD4 + Foxp3 À T cells, using the bicistronic, Foxp3-eGFP-transgenic B6 mouse line, in which Foxp3 + cells co-express the fluorescent green marker 28 .
Transferred Foxp3 À CD4 + T cells showed little (B0.1%) conversion to CD4 + Foxp3 + cells in spleen or VAT (Fig. 4a) , but recipient mice were as protected from weight gain as mice receiving full CD4 + T cell grafts from WT hosts (Fig. 4b) .
CD4 + Foxp3 À T cells were equally sufficient to improve glucose tolerance, fasting glucose and fasting insulin concentrations (Fig. 4c,d ), suggesting that metabolic control after CD4 + T cell transfer does not require CD4 + Foxp3 + regulatory T cell function in our adoptive transfer model. Regulatory T cells and inducible type 1 regulatory T cells produce IL-10, a major anti-inflammatory cytokine, as part of their effector function 29 . Adoptive transfer of CD4 + T cells from IL-10-null B6 mice was as protective as full WT CD4 + grafts, indicating that T cell-derived IL-10 is dispensable for the beneficial effects of CD4 + T cells ( Fig. 4b-d ).
T cells can acquire a T H 2 profile during the extensive homeostatic expansion that occurs after transfer into Rag1-null mice, and we observed considerable T H 2 cytokine production (IL-4 and IL-13) in VAT-derived T cells of HFD-fed Rag1-null CD4 + T cell recipients (Fig. 4e) . Maintenance of T H 2 cells is largely dependent on signal transducer and activator of transcription-6 (STAT6), and STAT6 deficiency severely impairs, without completely ablating the T H 2 sublineage, which can be identified by the GATA-3 transcription factor [30] [31] [32] . To determine the role of T H 2 cells in our transfer model, we transferred CD4 + STAT6-null T cells into HFD-fed Rag1-null mice. As expected, recipients of CD4 + STAT6-null T cells generated reduced numbers of CD4 + GATA-3 + (T H 2) T cells in VAT compared to mice receiving WT CD4 + T cells (Fig. 4f) . CD4 + STAT6-null T cells lacked most of the positive CD4 + impact on glucose tolerance, fasting glucose, fasting insulin and weight gain, identifying metabolic effects of T H 2 cells in the CD4 + T cell transfer model (Fig. 4g,h) . The implication of T H 2 cells, as regulators of glucose homeostasis in the transfer model, prompted us to compare this subset in VAT of NCD-fed and HFD-fed WT mice (Fig. 4i,j) . The proportions of T H 2 (CD4 + GATA-3 + ) cells were significantly lower (B50%) in VAT of HFD-fed mice (Fig. 4i,j) ; however, the absolute numbers of T H 2 cells/ gram of VAT remained fairly constant (Fig. 4j) . As is the case with CD4 + Foxp3 + T cells, our results suggest that smaller T H 2 cell proportions in DIO-associated VAT represent a candidate mechanism for worsening metabolic control in progressively obese mice, and strategies that increase VAT T H 2 cell content might be of therapeutic benefit.
Immunotherapy of insulin resistance
The various DIO-associated metabolic parameters relevant here are complex, and immune controls probably involve multiple levels and mechanisms. Although the scarcity of CD4 + Foxp3 + T cells in DIOassociated VAT implicated these cells in metabolic controls, the adoptive transfer model did not. To gain more insight into this issue, we used immunotherapy to possibly reset the diet-induced shifts in VAT T cell constituents, as in vivo CD3-specific antibody function depends on the CD4 + Foxp3 + T cell compartment for its long-term tolerogenic effects 23, 33 .
We injected mitogenic CD3-specific antibody 34 (10 mg d À1 over 5 d) into 14-week-old HFD-fed WT mice. This protocol promotes T cell self-tolerance through global, transient (r3 weeks) T cell depletion, paralleled by a selective increase of CD4 + Foxp3 + T cell pools in sites of tissue inflammation 23, 33 . Nine weeks after CD3-specific antibody treatment, HFD mice had near lean levels of CD4 + Foxp3 + T cells in VAT (Fig. 5a) . Treatment improved fasting glucose and insulin levels and greatly improved glucose tolerance and insulin sensitivity ( Fig. 5b-d ). There was a transient weight loss, lasting 3-4 weeks after CD3-specific antibody injection (Fig. 5e ). This was probably attributable to the cytokine storm after initial T cell activation, with TNF-a a major mediator 35, 36 , as the differences in body weight, adipocyte hypertrophy, food intake, CO 2 production and O 2 consumption disappeared over the following weeks on continued HFD ( Fig. 5e and Supplementary Fig. 6d ). CD3-specific antibodymediated normalizing effects on insulin resistance and glucose tolerance emerged 3-4 weeks after injection and lasted the entire observation period (Z4 months, Supplementary Fig. 7a-d) , despite continued exposure to the hypercaloric diet. We observed a similar but slightly less effective impact on metabolic parameters after treatment of leptin-deficient ob/ob mice with CD3-specific antibody ( Supplementary Fig. 7e-i) . Reduced efficiency of CD3-specific antibody in ob/ob mice correlated with reduced restoration of T regulatory cell numbers in VAT ( Supplementary Fig. 7e ), probably owing to the multiple immune abnormalities associated with leptin deficiency 37 .
Adverse effects of the cytokine storm may limit the utility of intact CD3-specific antibody therapy. We therefore tested the non-mitogenic F(ab¢) 2 fragment of CD3-specific antibody 34 . Injection of 150 mg of F(ab¢) 2 per d over 5 d resulted in long-term improvements of glucose tolerance and fasting glucose and insulin concentrations (Fig. 5f ) without weight loss (Fig. 5g) in HFD-fed mice. F(ab¢) 2 treatment also restored CD4 + Foxp3 + T cell numbers in VAT (Fig. 5h) . Notably, the IFN-g + T H 1 bias and the abundance of other VAT cytokines measured remained unchanged by F(ab¢) 2 therapy (Fig. 5i,j) , again pointing to, but not proving, that restoration of VAT T regulatory cells improves long-term glucose and insulin homeostasis.
CD4 + Foxp3 + T cells can induce M2 AAMs 12 , which secrete IL-10 and protect against insulin resistance 38 . To determine whether the restoration of VAT regulatory T cells by CD3-specific antibody immunotherapy did, in fact, generate IL-10-secreting M2 macrophages, we established cytokine profiles of M2 macrophages on the basis of surface staining of MMR. We distinguished three F4/80 + macrophage populations in VAT of both HFD-and NCD-fed mice: MMR À , MMR lo and MMR hi macrophages (Fig. 6a) . Only MMR hi macrophages expressed IL-10; MMR lo macrophages were the largest source of MCP-1, and MMR À macrophages expressed MCP-1 and TNF-a, likely representing classical M1 macrophages (Fig. 6b) .
Notably, diet had little effect on these cytokine patterns (Fig. 6b) . However, HFD-fed mice generated more MMR À macrophages and less IL-10-secreting MMR hi macrophages compared to NCD-fed mice (Fig. 6a) . F(ab¢) 2 therapy increased the MMR hi pool and reduced the MMR À pool by 6 weeks after treatment (Fig. 6c ). This macrophage shift generated an B300% increase in IL-10 production, as measured in purified VAT macrophages from F(ab¢) 2 -treated DIO mice (Fig. 6d) . F(ab¢) 2 therapy seems to have dual functions, increasing both anti-inflammatory T cell and macrophage compartments in VAT.
DISCUSSION
We identified a fundamental role for CD4 + T lymphocytes in the regulation of body weight, adipocyte hypertrophy, insulin resistance and glucose tolerance, implicating these cells in the control of disease progression in DIO and the ob/ob form of type 2 diabetes. We revealed the lymphocyte impact with independent models and experiments, including Rag1-null mice, which develop an overtly diabetic phenotype on a HFD.
Our evidence maps T cell-mediated metabolic rescue to both, CD4 + Foxp3 + and CD4 + Foxp3 À (for example, T H 2) T cell compartments. Whereas CD4 + Foxp3 À cells affected obesity and insulin resistance, CD4 + Foxp3 + cells primarily regulated insulin resistance, although this was not as apparent in our adoptive transfer models, where T H 2 cells emerged as regulators of obesity and insulin resistance. Overall, our experiments do not rule out effects of B lymphocytes or VAT-associated innate lymphocyte subsets (for example, NK, NKT, TCRg/d or CD4 À CD8 À TCRa/b + subsets) 24 . In fact, our preliminary data suggest that B cell deficiency in DIO mice is associated with improved metabolic control (S.W., Y.C., G.P. and H.-M.D. unpublished data).
We primarily focused on mouse models, but our limited human studies support the conclusions we drew from the mouse experiments. VAT of DIO mice and obese humans is characterized by an abnormally high T H 1 to Foxp3 + cell ratio; high expression of IFN-g in human VAT was previously associated with increased waist circumference 17 . IFN-g is a proinflammatory cytokine, and increased numbers of T H 1 cells in VAT may contribute to insulin resistance, an observation supported by improved glucose tolerance in T H 1 cell-deficient, IL-12p35-null mice (S.W., Y.C., H.T. and H.-M.D., unpublished data) and in IFN-g-null mice 39 . We favor a model where a relatively constant pool of CD4 + Foxp3 + and T H 2 fat-associated T cells gradually fails to limit expanding pools of T H 1 cells, leading to a progressively proinflammatory environment that promotes insulin resistance. It is also possible that T regulatory cell function may be suboptimal in the inflammatory VAT environment, as suggested in autoimmune disease models 40 . Factors that drive T H 1 cell influx, expansion or both in VAT are unknown but now appear to include antigen-driven expansion, with a role for classical immune elements such as the T H 1 chemokine RANTES 18 .
The precise mechanisms by which CD4 + T cells affect insulin sensitivity require further study. The induction of IL-10-secreting M2 macrophages represents one potential mechanism, although we ruled out such a role for T cell-derived IL-10. CD4 + Foxp3 + T cells induce M2c-type AAMs through production of IL-10 and TGF-b, whereas T H 2 T cells can induce M2a-type AMMs 13 . AAMs can regulate insulin resistance through IL-10-mediated reversal of TNFa-induced insulin resistance 15 . AAMs are present in adipose tissue of lean mice, but, as obesity ensues, there is a shift to proinflammatory M1 macrophages 15 . This shift to M1 macrophages is probably a result of steadily increasing T H 1 to Foxp3 + and T H 1 to T H 2 cell ratios. In fact, we observed increases in VAT M2 macrophages and decreases in M1 macrophages after restoration of CD4 + Foxp3 + T cell pools after F(ab¢) 2 immunotherapy.
CD3-specific antibody is a potent, clinically used immunosuppressant, and a possible therapeutic in type 1 diabetes 34, 41 . Its immune effects are reversible, well understood and easily monitored. The data presented here suggest that it may be of use in the treatment of insulin resistance. In such individuals, use of CD3-specific antibody may have multiple benefits, as it is effective in reducing atherosclerotic plaques, common in obesity and insulin resistance syndromes 42 . We observed a similar but slightly less effective course of CD3-specific antibody immunotherapy in diabetic, leptin-deficient ob/ob mice. However, leptin affects multiple pathways in the immune response, including TGF-b signaling, T cell homeostasis and macrophage and dendritic cell maturation 43, 44 . CD3-specific antibody immunotherapy requires TGF-b secretion by phagocytes, and deficiencies in this pathway may account for somewhat reduced efficiency in leptindeficient mice 45 .
Although we focused on the metabolic roles of lymphocytes in VAT, we cannot rule out lymphocyte impact on insulin resistance in other organs such as the liver. We also cannot rule out a role for CD8 + T cells in disease development. Although transfer studies show that CD8 + T cells in isolation have little impact on obesity and associated insulin resistance, it is possible that, with CD4 + T cell help, CD8 + T cells and possibly the regulatory CD8 + subsets 33 become more active participants.
Our perhaps most unexpected discovery was the TCR V a bias in DIO OT2 and B6 mice. Antigen-driven T cell selection and expansion in VAT would be the most likely explanation, substantially supported by the failure of exclusively OVA-specific T cells to transfer the protective functions of T H 2 and Foxp3 + T cell compartments. Further validation, through identification of candidate adipose tissue epitopes, would imply autoimmunity in obesity, where VAT selective adipocyte death has, in fact, already been described 46 .
Collectively, we have shown a previously unknown role for the adaptive immune system in the regulation of obesity, fat distribution and insulin resistance. Our observations identify several T cell populations as physiological regulators in these processes, and they identify VAT-selective, TCR-dependent, cognate immunity as one element driving T cell expansion in VAT. This observation strongly implies that VAT incites active T cell immunity. Work is underway to identify the inciting antigenic epitopes to open a door to globally affordable tolerogenic vaccination strategies against DIO and, possibly, its associated metabolic syndromes, including type 2 diabetes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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